Form 4 for PCVX Vaxcyte, Inc.
Accepted 2025-08-29 00:00:00 ET · period of report 2025-08-29 · accession 0001960048-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-29 | 2025-09-07 | PCVX | Cowan Elvia | SVP, Fin | A - Grant | $0.00 | +2,810 | 27.2K | +12% | $0 |
| D | 2025-08-29 | 2025-08-29 | PCVX | Cowan Elvia | SVP, Fin | A - Grant | $0.00 | +9,743 | 9,743 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-07 | A | A | 2,810 | $0.00 | 27,205 | D | — | — | (F1) Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on March 7, 2026 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. (F2) Includes 289 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025. |
| 2 | Derivative | Stock Option (right to buy) | 2025-08-29 | A | A | 9,743 | $0.00 | 9,743 | D | $30.79 · — to 2035-08-29 | 9,743 Common Stock | (F3) 1/48 of shares subject to the option vest on September 29, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |